CA2523079A1 - Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts - Google Patents
Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts Download PDFInfo
- Publication number
- CA2523079A1 CA2523079A1 CA002523079A CA2523079A CA2523079A1 CA 2523079 A1 CA2523079 A1 CA 2523079A1 CA 002523079 A CA002523079 A CA 002523079A CA 2523079 A CA2523079 A CA 2523079A CA 2523079 A1 CA2523079 A1 CA 2523079A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical preparation
- carrier
- water
- preparation according
- edta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a solid pharmaceutical preparation containing water-soluble salts of Levothyroxine and/or Liothyronine as active agent, wherein water activity of the pharmaceutical preparation measured at room temperature is set to values below 0.4, preferably 0.1 to 0.3.
Claims (15)
1. A solid pharmaceutical preparation containing water-soluble salts of levothyroxine and/or liothyronine as active ingredients, characterized in that the water activity of said pharmaceutical preparation is adjusted to values of below 0.4 and above 0.1, measured at room temperature.
2. A pharmaceutical preparation according to claim 1, characterized in that the water activity of said pharmaceutical preparation is adjusted to values ranging from 0.1 to 0.3, measured at room temperature.
3. A pharmaceutical preparation according to claim 1 or 2, characterized in that the active ingredient from a methanolic/ethanolic solution is homogenously applied on a carrier optionally mixed with starch, guar or granulation aids.
4. A pharmaceutical preparation according to claim 1, 2 or 3, characterized in that the active ingredient is applied on a water-soluble carrier.
5. A pharmaceutical preparation according to any one of claims 1 to 4, characterized in that mannitol is used as a water-soluble carrier.
6. A pharmaceutical preparation according to any one of claims 1 to 5, characterized in that the carrier is treated with an amount of EDTA-Na substantially corresponding to the Ca++-content of the carrier, and optionally citric acid.
7. A pharmaceutical preparation according to any one of claims 1 to 6, characterized in that the preparation is present in the form of tablets and confectioned with non-hygroscopic adjuvants and/or in a package with only little or no water-vapor permeability.
8. A method for producing a pharmaceutical preparation according to any one of claims 1 to 7, characterized in that a carrier of mannitol is coated or sprayed with an alcoholic solution of the active ingredient, whereupon the alcoholic solvent is evaporated until a water factor of below 0.4 and, in particular, below 0.3 and above 0.1 has been reached, and tableting is subsequently effected.
9. A method according to claim 8, characterized in that water or an aqueous solution containing EDTA-Na and/or citric acid is applied prior to evaporating said solvent.
10. A method according to claim 8 or 9, characterized in that directly tabletable mannitol and, in particular, Pearlitol is used as a carrier.
11. A method according to claim 8, 9 or 10, characterized in that hydrophobic adjuvants such as, e.g., magnesium stearate are used as tableting aids and, in particular, lubricants.
12. A method according to any one of claims 8 to 11, characterized in that the carrier, prior to being coated or sprayed with the active ingredient solution is supplemented with EDTA-Na and optionally citric acid, in an amount sufficient for complexing bivalent ions of the carrier and other sources such as solvents.
13. A method according to any one of claims 8 to 12, characterized in that the carrier is wetted with methanol prior to being supplemented with EDTA-Na and optionally citric acid.
14 14. A method according to any one of claims 8 to 13, characterized in that the composition is kept free of hygroscopic adjuvants.
15. A method according to any one of claims 8 to 13, characterized in that the composition contains hygroscopic adjuvants, yet is packed in a water-vapor-tight package.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA667/2003 | 2003-05-02 | ||
AT6672003 | 2003-05-02 | ||
PCT/AT2004/000150 WO2004096177A1 (en) | 2003-05-02 | 2004-05-03 | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2523079A1 true CA2523079A1 (en) | 2004-11-11 |
CA2523079C CA2523079C (en) | 2012-08-14 |
Family
ID=33314944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2523079A Expired - Lifetime CA2523079C (en) | 2003-05-02 | 2004-05-03 | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1622587B1 (en) |
JP (1) | JP5414146B2 (en) |
AT (1) | ATE465718T1 (en) |
AU (1) | AU2004234176B2 (en) |
BR (1) | BRPI0410021A (en) |
CA (1) | CA2523079C (en) |
DE (1) | DE502004011103D1 (en) |
DK (1) | DK1622587T3 (en) |
ES (1) | ES2344294T3 (en) |
PT (1) | PT1622587E (en) |
RU (1) | RU2361573C2 (en) |
WO (1) | WO2004096177A1 (en) |
ZA (1) | ZA200509026B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012438B2 (en) | 2002-11-13 | 2015-04-21 | Aldo Pinchera | 3,5,3′ -triiodothronine sulfate as thyromimetic agent and pharmaceutical formulations thereof |
US9890116B2 (en) | 2002-11-13 | 2018-02-13 | Bracco Imaging S.P.A. | Process for the preparation of a sulfated derivative of 3,5-diiodo-O-[3-iodophenyl]-L-tyrosine |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2897267A1 (en) * | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | MULTIMICROPARTICULAR PHARMACEUTICAL FORMS FOR PER OS ADMINISTRATION |
US20100119601A1 (en) * | 2007-04-11 | 2010-05-13 | Pharmaceutical Productions Inc. | Melatonin tablet and methods of preparation and use |
HUE035222T2 (en) * | 2012-08-20 | 2018-05-02 | Merck Patent Gmbh | Solid pharmaceutical preparation containing levothyroxine |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225204A (en) | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
DE19541128C2 (en) * | 1995-10-27 | 1997-11-27 | Henning Berlin Gmbh & Co | Stabilized thyroid hormone-containing medicines |
US5635209A (en) * | 1995-10-31 | 1997-06-03 | Vintage Pharmaceuticals, Inc. | Stabilized composition of levothyroxine sodium medication and method for its production |
US5955105A (en) * | 1995-11-14 | 1999-09-21 | Knoll Pharmaceutical Company | Stabilized thyroid hormone preparations and methods of making same |
JP2001114712A (en) * | 1996-04-16 | 2001-04-24 | Takeda Chem Ind Ltd | D-mannitol and method for producing the same |
DE19653410A1 (en) * | 1996-12-20 | 1998-06-25 | Basf Ag | Use of carotenoid solubilisates for coloring food and pharmaceutical preparations |
CA2272402A1 (en) * | 1997-11-17 | 1999-05-27 | Gist-Brocades B.V. | Granules comprising clavulanate and one or more excipients |
JP3274416B2 (en) * | 1998-05-29 | 2002-04-15 | 佐藤製薬株式会社 | Orally disintegrating granular preparation |
FR2781793B1 (en) | 1998-08-03 | 2001-07-20 | Prographarm Lab | PROCESS FOR PRODUCING COATED GABAPENTINE GRANULES |
JP2000060535A (en) * | 1998-08-21 | 2000-02-29 | Kyowa Hakko Kogyo Co Ltd | Preservation of microorganismal cell |
JP3491887B2 (en) * | 1999-04-28 | 2004-01-26 | フロイント産業株式会社 | Method for producing aggregates of sugar alcohol granules |
GB9919487D0 (en) * | 1999-08-17 | 1999-10-20 | Nestle Sa | Moulded onfectionery product comprising vegetables |
JP4677084B2 (en) * | 1999-09-30 | 2011-04-27 | 武田薬品工業株式会社 | Solid preparation containing bromhexine hydrochloride |
US6399101B1 (en) * | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
AU7307101A (en) * | 2000-06-30 | 2002-01-14 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
ES2174734B1 (en) * | 2000-11-03 | 2003-10-01 | Belmac S A Lab | NEW GALENIC FORMULATION OF DISPERSABLE AND SOLUBLE PARACETAMOL, PROCEDURE FOR PREPARATION AND APPLICATIONS. |
JP2004525109A (en) * | 2001-02-15 | 2004-08-19 | キング・ファーマシューティカルズ・インコーポレイティッド | Stabilized thyroid hormone pharmaceutical composition and method for producing the same |
JP4291962B2 (en) * | 2001-03-27 | 2009-07-08 | あすか製薬株式会社 | Stable thyroid hormone-containing solid pharmaceutical composition |
EP1461307A2 (en) | 2002-01-07 | 2004-09-29 | Abbott GmbH & Co. KG | Crystallization of amino acids using ultrasonic agitation |
-
2004
- 2004-05-03 AT AT04730797T patent/ATE465718T1/en active
- 2004-05-03 PT PT04730797T patent/PT1622587E/en unknown
- 2004-05-03 EP EP04730797A patent/EP1622587B1/en not_active Revoked
- 2004-05-03 DK DK04730797.0T patent/DK1622587T3/en active
- 2004-05-03 WO PCT/AT2004/000150 patent/WO2004096177A1/en active Search and Examination
- 2004-05-03 DE DE502004011103T patent/DE502004011103D1/en not_active Expired - Lifetime
- 2004-05-03 RU RU2005137577/15A patent/RU2361573C2/en active
- 2004-05-03 AU AU2004234176A patent/AU2004234176B2/en not_active Ceased
- 2004-05-03 CA CA2523079A patent/CA2523079C/en not_active Expired - Lifetime
- 2004-05-03 BR BRPI0410021-2A patent/BRPI0410021A/en not_active Application Discontinuation
- 2004-05-03 ES ES04730797T patent/ES2344294T3/en not_active Expired - Lifetime
- 2004-05-03 JP JP2006503952A patent/JP5414146B2/en not_active Expired - Lifetime
-
2005
- 2005-11-08 ZA ZA200509026A patent/ZA200509026B/en unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012438B2 (en) | 2002-11-13 | 2015-04-21 | Aldo Pinchera | 3,5,3′ -triiodothronine sulfate as thyromimetic agent and pharmaceutical formulations thereof |
US9044441B2 (en) | 2002-11-13 | 2015-06-02 | Bracco S.P.A. | 3,5,3′-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof |
US9468619B2 (en) | 2002-11-13 | 2016-10-18 | Bracco S.P.A. | 3,5,3′-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof |
US9890116B2 (en) | 2002-11-13 | 2018-02-13 | Bracco Imaging S.P.A. | Process for the preparation of a sulfated derivative of 3,5-diiodo-O-[3-iodophenyl]-L-tyrosine |
US10238615B2 (en) | 2002-11-13 | 2019-03-26 | Bracco S.P.A. | 3,5,3′-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof |
US10457635B2 (en) | 2011-04-08 | 2019-10-29 | Bracco Imaging S.P.A. | Process for the preparation of a sulfated derivative of 3,5-diiodo-o-[3-iodophenyl]-l-tyrosine |
Also Published As
Publication number | Publication date |
---|---|
JP5414146B2 (en) | 2014-02-12 |
DE502004011103D1 (en) | 2010-06-10 |
RU2361573C2 (en) | 2009-07-20 |
WO2004096177A1 (en) | 2004-11-11 |
RU2005137577A (en) | 2006-05-10 |
ATE465718T1 (en) | 2010-05-15 |
EP1622587A1 (en) | 2006-02-08 |
ZA200509026B (en) | 2007-03-28 |
CA2523079C (en) | 2012-08-14 |
ES2344294T3 (en) | 2010-08-24 |
AU2004234176A1 (en) | 2004-11-11 |
DK1622587T3 (en) | 2010-08-23 |
PT1622587E (en) | 2010-07-07 |
AU2004234176B2 (en) | 2010-05-13 |
EP1622587B1 (en) | 2010-04-28 |
JP2006525234A (en) | 2006-11-09 |
BRPI0410021A (en) | 2006-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY151470A (en) | Controlled release solid preparation | |
EA200602175A1 (en) | AGLOMERATION OF CALCIUM CONTAINING COMPOUNDS BY PRESSING ON ROLLS | |
GR3031135T3 (en) | Compositions containing S(+)-Ibuprofen. | |
IS4329A (en) | Tablet unit dosage form containing proton pump blocker | |
IS5404A (en) | Pharmaceutical preparation containing chloronate as the active ingredient and silicified microcrystalline cellulose as a carrier | |
CA2251886A1 (en) | An oral pharmaceutical formulation containing ibandronate | |
EE03089B1 (en) | Effervescent formulation containing ibuprofen and method for its preparation | |
CA2003190A1 (en) | Pharmaceutical compositions containing n-(3,4-dimethoxycinnamoyl) anthranilic acid | |
CA2326662A1 (en) | Therapeutic system which can be moisture-activated | |
JP2003212682A5 (en) | ||
IS6511A (en) | Pharmaceutical preparations containing sugar fatty acid esters to control the release of active ingredients | |
CA2523079A1 (en) | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts | |
MXPA02012889A (en) | 4-alkoxy cyclohexane-1 amino carboxylic acid esters and method for the production thereof. | |
ES2138242T3 (en) | METHOD FOR MANUFACTURING SOLUTIONS, IN POLYHYDROXYLATED ALCOHOLS, OF ANTI-TRANSPARENT ACTIVE INGREDIENTS OF IMPROVED EFFICIENCY. | |
US4067974A (en) | Stabilized solid form choline salicylate compositions | |
US8293272B2 (en) | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts | |
GR20070100405A (en) | Improved pharmaceutical composition containing acetylcholine esterace inhibitor and method for the preparation thereof | |
CN102670648A (en) | Liquid iodine disinfectant, preparation method and used container thereof | |
CA2373962A1 (en) | Immediate release medicinal compositions for oral use | |
JPH06239701A (en) | Vitality-reserving agent for cut flower and method therefor | |
NZ505080A (en) | Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid | |
JPS57118509A (en) | Novel preparation of high absorbability | |
MD1779G2 (en) | Dermatologic film-forming composition with juglone (variants) | |
JPH08109106A (en) | Plant growth promotor | |
RU2002107913A (en) | Pharmaceutical composition of thyroid hormone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |